April 14, 2021


Advances in world technology

Significant development created in new COVID-19 vaccine produced by the crew of Prof Salanti

STOCKHOLM, Jan. 13, 2021 /PRNewswire/ — On Tuesday January 12th, in Mother nature Communications, sturdy preclinical final results for a new COVID-19 vaccine, made by the team of Prof. Salanti from University of Copenhagen, ExpreS2ion Biotech, its joint undertaking partner AdaptVac and the Avoid-nCoV consortium, was posted. Primarily based on these outcomes, a scientific demo application (CTA) for a scientific Stage I/II examine for the COVID-19 vaccine has been submitted.

About the preclinical results
Readouts from the data clearly show that ABNCoV2 has the likely to be the best-in-class COVID-19 vaccine with a a lot more than 100-fold increased level of neutralizing antibodies in contrast with revealed preclinical animal data from at the moment approved COVID-19 vaccines, these kinds of as Pfizer-BioNTech’s, Moderna’s, and AstraZeneca-Oxford’s vaccines. The entire paper is out there on the net and can be read through below.

About the CTA
The Clinical trial application (CTA) for the ABNCoV2 capsid virus-like particle (cVLP) dependent COVID-19 vaccine was submitted to the Central Committee on Research Involving Human Topics (CCMO) in the Netherlands past week. It is expected to be approved less than a COVID-19 quick-monitor critique progress. This can be found as an additional major milestone adhering to the November 2020 announcement of the thriving GMP production of the vaccine. ExpreS2ion expects to current preliminary medical Stage I/IIa success prior to stop of Q1 2021.         

Attana’s involvement
Due to the fact March 2020, Attana has been helping the workforce of Prof. Ali Salanti at the University of Copenhagen in the development of this COVID-19 vaccine with two of Attana’s QCM Biosensors merged with study intelligence. As can be found in the paper revealed, Attana’s technological innovation has foremost been used to analyze kinetic interactions concerning RBD antigens and CLP-RBD to hACE2. On top of that, Attana and ExpreS2ion not long ago recognized a strategic partnership together with a source agreement of proteins. In addition, Attana technology has been utilised to high quality command the vaccine for the IND submission.

Attana CEO Teodor Aastrup responses:
“I’m thrilled for our partners sake and for the long run of vaccine enhancement and want to congratulate all functions included for acquiring this sort of fascinating success. I’m now wanting ahead to explore this collaboration more and to hopefully do the job a lot more carefully with each Prof. Salanti and the group at ExpreS2ion in the around time long term.”

For far more information and facts, you should speak to:

Teodor Aastrup
[email protected]
+46 () 8 674 57 00

The Board of administrators for Attana consider that the data in this push launch is not very likely to have a significant impact on the share cost but is of typical desire for the shareholders and that’s why need to be communicated.

About Attana

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Due to the fact then, Attana has produced proprietary label no cost biosensors for biochemical, crude, sera, and mobile-based mostly assays and the Attana Virus Analytics (AVA) platform, a proprietary in-vitro diagnostics (IVD) software. Attana products and exploration solutions are employed by Big Pharma, biotech providers and tutorial institutions inside the existence sciences. To discover more about our most current solutions and products, be sure to visit www.attana.se or get in touch with [email protected].

This information was introduced to you by Cision http://news.cision.com


The following information are available for down load:

Source Attana